Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 9Lymphoid 4CNS 4Myeloid 2Gynecologic 2Sarcoma 1Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Neuroblastoma 4Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × IL32 protein, human × CNS × Clear all
NCT02573896 2026-03-23

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting
13 enrolled
CNS

Neuroblastoma

NCT04211675 2025-05-13

STING

Nationwide Children's Hospital

Phase 1/2 Recruiting
31 enrolled
CNS

Neuroblastoma

NCT02100891 2025-03-19

STIR

Medical College of Wisconsin

Phase 2 Terminated
15 enrolled 11 charts
CNSSarcoma

Brain Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms

NCT01576692 2018-11-15

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

St. Jude Children's Research Hospital

Phase 1 Completed
34 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡